Pharmaceutical / Drug Definition :
Inhibits cholinergic receptors in bronchial smooth muscle, decreasing level of cyclic guanosine monophosphate and dilating bronchioles. When used locally, inhibits secretions from glands lining the nasal mucosa.
In the United States, Ipratropium Bromide is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Ipratropium Bromide.
FDA Label Requirements and Exceptions
FDA Import Information
Ipratropium Bromide (Ipratropium Bromide Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Ipratropium Bromide (Ipratropium Bromide Suppliers)
- Processors Ipratropium Bromide
- Repackers Ipratropium Bromide
- Relabelers Ipratropium Bromide
- Exporters Ipratropium Bromide
- Importers Ipratropium Bromide
For more information about Ipratropium Bromide, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.